MGMT repairs O6-methylguanine DNA damage that is induced by alkylating agents such as temozolomide (currently the mainstay of anti-glioma chemotherapy), and strategies to overcome this resistance have been the focus of many studies [299,300]. The gene discussed is MGMT; the disease is central nervous system cancer.